Proteus Digital Health

By Dave Muoio October 15, 2018
Proteus Digital Health and Otsuka Pharmaceutical have expanded their partnership on digital therapeutics. On Thursday, Proteus announced that it received $88 million from the pharma company, which will go toward the continued development and commercialization of its ingestible sensor pill platform. Additionally, the five-year deal will also support the investigation of a wider digital medicine...
By Dave Muoio August 30, 2018
Otsuka Pharmaceuticals and Proteus Digital Health’s sensor-carrying pill Abilify MyCite is on its way to US patients thanks to a new collaboration agreement between Otsuka and Magellan Health. Announced this morning by the pharmaceutical company, the rollout will initially be limited to give Otsuka and Magellan a better idea of how best to deploy the technology at scale. “We are eager for...
By Dave Muoio August 21, 2018
Anthem Blue Cross and Blue Shield in Ohio has partnered with Propeller Health to provide sensor-equipped inhaler attachments to plan members with COPD. The rollout will give members access to Propeller’s medication tracker app, while providing an online provider portal for the insurer’s care management team. “There’s currently no cure for COPD, but much can be done to help consumers treat the...
By Dave Muoio July 26, 2018
Proteus Digital Health’ pitch to track adherence using sensor-equipped pills has found another audience in the HIV prevention community. Among the featured data presented at this week’s International AIDS Conference in Amsterdam was a trial that outfitted Gilead Sciences’ preventive HIV drug Truvada (tenofovir/emtricitabine) with the tracking technology. Here, researchers found that the sensor-...
By Dave Muoio March 8, 2018
It’s still the early days, but the FDA’s approval of Proteus Digital Health and Otsuka Pharmaceuticals’ Abilify MyCite has changed the discussion of digital technology in healthcare. The first approval of drug delivery via a sensor-equipped pill sparked debates over the tradeoff of privacy for medication adherence, and whether these types of technologies would find a role in future healthcare....
By Dave Muoio February 19, 2018
Ann Mond Johnson will be taking over as CEO of the the American Telemedicine Association in early March, according to a statement released last week. She previously served as the CEO of Zest Health, served as board chair and advisor to ConnectedHealth, and has a history of entrepreneurship. The CEO position’s previous occupant, Jonathan Linkous, stepped down last year after 24 years at the...
By Jonah Comstock November 17, 2017
Correction: An earlier version of this article was unclear about differences between Abilify MyCite and the Proteus Digital Medicine Platform.  Earlier this week, Proteus Digital Health and Otsuka Pharmaceuticals announced that Abilify MyCite, a new, sensor-enabled version of Otsuka’s drug for schizophrenia, had received FDA approval for mental health conditions including schizophrenia and...
By Dave Muoio November 15, 2017
Connected wearable patch makers will ship 35.1 million units annually by 2022, with 80 percent of these being used in clinical applications, according to a recent report from market intelligence firm Tractica. The report also forecasts a total $7.9 billion in revenue for the patch market by the same year, all of which suggests a substantial escalation from the 966,000 units the analysts wrote...
By Jonah Comstock September 7, 2017
Proteus Digital Health has made a high-profile addition to its board of directors: Dr. Regina Benjamin, who served as US Surgeon General from 2009 to 2013. "I am honored and excited to join the board of Proteus Digital Health,” Benjamin said in a statement. “As a nation, we are facing increasing challenges with chronic illnesses such as hypertension, diabetes, heart disease, hepatitis, behavioral...
By Jonah Comstock May 23, 2017
One year after the FDA declined to approve Proteus Digital Health and Otsuka's new sensor-embedded formulation of Otsuka's antipsychotic drug Abilify, the companies are giving it another shot, resubmitting the application with additional information. As before, the application is a New Drug Application (NDA) -- both the Proteus system itself and Abilify are already FDA cleared and approved,...